Top

Drug Safety

Published in:

01-06-2009 | Original Research Article

Topical Corticosteroids and the Risk of Diabetes Mellitus

A Nested Case-Control Study in the Netherlands

Authors: Michiel W. van der Linden, Dr Fernie J. A. Penning-van Beest, Tamar Nijsten, Ron M. C. Herings

Published in: Drug Safety | Issue 6/2009

Abstract

Background: The relationship between topical corticosteroid use, potency, treatment duration, concomitant exposure to systemic corticosteroids, and risk of diabetes has been incompletely studied.

Objective: To investigate an association between intense, longstanding topical corticosteroid use and diabetes mellitus.

Methods: Data for this nested case-control study were obtained from the PHARMO Record Linkage System, including linked drug dispensing and hospital records of >2.5 million individuals in defined areas of the Netherlands. Users of topical corticosteroids during 1992–2004, without diabetes, with ≥2 topical corticosteroid dispensings and ≥4 years of follow-up were selected. Diabetes onset was defined as first occurrence (index date) of an antidiabetic drug dispensing or hospitalization for diabetes. Cases were matched 1:4 by age and sex to controls, with ≥2 topical corticosteroid dispensings and similar follow-up duration. Use of topical corticosteroids and systemic corticosteroids and/or inhaled corticosteroids as co-medication was classified as current, recent and past/never (≤2 years, 2–4 years and >4 years ago, respectively). Multivariate regression analyses were adjusted for co-medication and co-morbidity.

Results: Among 192 893 incident topical corticosteroid users, 2212 developed diabetes and could be matched to 8582 controls. Current topical corticosteroid use was associated with an (unadjusted) 1.24-fold increased risk of diabetes (unadjusted OR 1.24; 95% CI 1.11, 1.40). The odds ratio increased to 1.32 with >180 days of topical corticosteroid use (95% CI 1.14, 1.54) and to 1.44 with a cumulative topical corticosteroid load (combined potency and amount) of 731–1460 mg (95% CI 1.21, 1.72). Among past/never users of systemic corticosteroids and/or inhaled corticosteroids, current use of topical corticosteroids remained associated with a 1.27-fold increased diabetes risk (unadjusted OR 1.27; 95% CI 1.10, 1.47) compared with past users of topical corticosteroids.

Conclusion: An increased risk of new-onset diabetes may be an important consideration in the treatment of patients with topical corticosteroids, especially when intense skin treatment is needed. Future studies are needed to endorse these findings in other populations.

Carruthers JA, August PJ, Staughton RC. Observations on the systemic effect of topical clobetasol propionate (Dermovate). Br Med J 1975; 4(5990): 203–4PubMedCrossRef

Nilsson JE, Gip LJ. Systemic effects of local treatment with high doses of potent corticosteroids in psoriatics. Acta Derm Venereol 1979; 59(3): 245–8PubMed

Levin C, Maibach HI. Topical corticosteroid-induced adrenocortical insufficiency: clinical implications. Am J Clin Dermatol 2002; 3(3): 141–7PubMedCrossRef

Abma EM, Blanken R, De Heide LJ. Cushing’s syndrome caused by topical steroid therapy for psoriasis. Neth J Med 2002; 60(3): 148–50PubMed

Gilbertson EO, Spellman MC, Piacquadio DJ, et al. Super potent topical corticosteroid use associated with adrenal suppression: clinical considerations. J Am Acad Dermatol 1998; 38 (2 Pt 2): 318–21PubMedCrossRef

Weber SL. Cushing’s syndrome attributable to topical use of lotrisone. Endocr Pract 1997; 3(3): 140–4PubMed

Reynolds RM, Syddall HE, Walker BR, et al. Predicting cardiovascular risk factors from plasma cortisol measured during oral glucose tolerance tests. Metabolism 2003; 52(5): 524–7PubMedCrossRef

Poa NR, Edgar PF. Insulin resistance is associated with hypercortisolemia in Polynesian patients treated with antipsychotic medication. Diabetes Care 2007; 30(6): 1425–9PubMedCrossRef

Sasaki N, Iwase M, Arima H, et al. Overt diabetes mellitus in a patient with combined primary aldosteronism and Cushing’s syndrome. Intern Med 2006; 45(21): 1237–42PubMedCrossRef

10.

Aalto-Korte K, Turpeinen M. Quantifying systemic absorption of topical hydrocortisone in erythroderma. Br J Dermatol 1995; 133(3): 403–8PubMedCrossRef

11.

Dekhuijzen PN, Honour JW. Inhaled corticosteroids and the hypothalamic-pituitary-adrenal (HPA) axis: do we understand their interaction? Respir Med 2000; 94(7): 627–31PubMedCrossRef

12.

Barnes N. The properties of inhaled corticosteroids: similarities and differences. Prim Care Resp J 2007; 16(3): 149–54CrossRef

13.

Dendukuri N, Blais L, LeLorier J. Inhaled corticosteroids and the risk of diabetes among the elderly. Br J Clin Pharmacol 2002; 54(1): 59–64PubMedCrossRef

14.

Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med 2002; 17(9): 717–20PubMedCrossRef

15.

Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care 2006; 29(12): 2728–9PubMedCrossRef

16.

Gomez EC, Frost P. Induction of glycosuria and hyperglycemia by topical corticosteroid therapy. Arch Dermatol 1976; 112(11): 1559–62PubMedCrossRef

17.

Sobngwi E, Lubin V, Ury P, et al. Adrenal insufficiency and diabetes mellitus secondary to the use of topical corticosteroids for cosmetic purpose. Ann Endocrinol (Paris) 2003; 64(3): 202–4

18.

Delea TE, Gokhale M, Makin C, et al. Administrative claims analysis of utilization and costs of care in health plan members with atopic dermatitis who had prior use of a topical corticosteroid and who initiate therapy with pime-crolimus or tacrolimus. J Manag Care Pharm 2007; 13(4): 349–59PubMed

19.

CDC National Center for Health Statistics. International classification of diseases. 9th rev., clinical modification (ICD-9-CM) [online]. Available from URL: http://www.cdc.gov/nchs/about/otheract/icd9/abticd9.htm [Accessed 2009 Mar 31]

20.

Herings RM. PHARMO: a record linkage system for post-marketing surveillance of prescription drugs in The Netherlands [dissertation]. Utrecht: Utrecht University, Department of Pharmaco-epidemiology and Pharmaco-therapy, 1993

21.

Hodari KT, Nanton JR, Carroll CL, et al. Adherence in dermatology: a review of the last 20 years. J Dermatolog Treat 2006; 17(3): 136–42PubMedCrossRef

22.

Herings RMC, de Jong R, on behalf of the PHARMO Institute for Drug Outcomes Research. Market exploration report: topical corticosteroids [in Dutch]. Utrecht: PHARMO Institute for Drug Outcomes Research, 2004

23.

Furue M, Terao H, Rikihisa W, et al. Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Br J Dermatol 2003; 148(1): 128–33PubMedCrossRef

24.

Koro CE, Fedder DO, L’Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002; 325(7358): 243PubMedCrossRef

25.

Citrome LL, Jaffe AB. Relationship of atypical anti-psychotics with development of diabetes mellitus. Ann Pharmacother 2003; 37(12): 1849–57PubMedCrossRef

26.

Feldman SR, Camacho FT, Krejci-Manwaring J, et al. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol 2007; 57(1): 81–3PubMedCrossRef

27.

Vlaski E, Stavric K, Isjanovska R, et al. Overweight hypothesis in asthma and eczema in young adolescents. Allergol Immunopathol (Madr) 2006; 34(5): 199–205CrossRef

28.

Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses’ Health Study II. Arch Intern Med 2007; 167(15): 1670–5PubMedCrossRef

29.

Boehncke S, Thaci D, Beschmann H, et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007; 157(6): 1249–51PubMedCrossRef

30.

Salas M, Hofman A, Stricker BH. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol 1999; 149(11): 981–3PubMedCrossRef

31.

Atherton DJ. Topical corticosteroids in atopic dermatitis. BMJ 2003; 327(7421): 942–3PubMedCrossRef

32.

Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000; 4(37): 1–191PubMed

33.

Callen J, Chamlin S, Eichenfield LF. A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol 2006; 152(2): 1–19

34.

Bruner CR, Feldman SR, Ventrapragada M, et al. A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol Online J 2003; 9(1): 2PubMed

35.

Van Der Meer JB, Glazenburg EJ, Mulder PG, et al. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic Dermatitis Study Group. Br J Dermatol 1999; 140(6): 1114–21

36.

Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ 2003; 326(7403): 1367PubMedCrossRef

37.

Boukes FS, Wiersma T, Cleveringa JP, et al. Summary of the practice guideline ‘atopic dermatitis’ (first revision) from the Dutch College of General Practitioners. Ned Tijdschr Geneeskd 2007; 151(25): 1394–8PubMed

38.

Bruijnzeel-Koomen CA, Sillevis Smitt JH, Boukes FS, et al. The practice guideline ‘atopic dermatitis’. Ned Tijdschr Geneeskd 2007; 151(25): 1399–402PubMed

39.

Charman CR, Morris AD, Williams HC. Topical cortico-steroid phobia in patients with atopic eczema. Br J Dermatol 2000; 142(5): 931–6PubMedCrossRef

40.

Charman C, Williams H. The use of corticosteroids and corticosteroid phobia in atopic dermatitis. Clin Dermatol 2003; 21(3): 193–200PubMedCrossRef

Title: Topical Corticosteroids and the Risk of Diabetes Mellitus
A Nested Case-Control Study in the Netherlands
Authors: Michiel W. van der Linden
Dr Fernie J. A. Penning-van Beest
Tamar Nijsten
Ron M. C. Herings
Publication date: 01-06-2009
Publisher: Springer International Publishing
Published in: Drug Safety / Issue 6/2009
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI: https://doi.org/10.2165/00002018-200932060-00008

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Topical Corticosteroids and the Risk of Diabetes Mellitus

A Nested Case-Control Study in the Netherlands

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2009

Understanding and Communicating Key Concepts in Risk Management

Safety and Drug Utilization Profile of Varenicline as Used in General Practice in England

Treatment of Chronic Non-Malignant Pain in the Elderly

Behavioural Adverse Effects of Dopaminergic Treatments in Parkinson’s Disease

An Evaluation of Three Signal-Detection Algorithms Using a Highly Inclusive Reference Event Database

NSAIDs and the Risk of Accidental Falls in the Elderly